论文部分内容阅读
以43例冠心病患为观察组,45名健康人为对照组,研究噻氯匹定对冠心病患者血小板聚集功能的影响.①治疗前,观察组的血小板聚集率(PAR)非常显著地高于对照组(P<0.001),且观察组中不同病变类型等亚组的PAR,在某些亚组间存在差异;②治疗后,观察组的PAR非常显著地低于治疗前(P0.06);③治疗后,观察组显效者31例(71.l%),改善者10例(23.3%),总有效率为95.4%.结果显示,噻氟匹定具有良好的抗血小板聚集作用,对冠心病的近期疗效较好.
The effect of ticlopidine on platelet aggregation in patients with coronary heart disease was investigated in 43 patients with coronary heart disease and 45 healthy people as control group.① Before treatment, the platelet aggregation rate (PAR) of the observation group was significantly higher than that of the control group (P <0.001). PAR in subgroups of different disease types in the observation group differed in some subgroups. (2) After treatment, PAR in the observation group was significantly lower than that before treatment (P < There was no significant difference between the two groups (P> 0.05). ③ After treatment, 31 cases (71.1%) showed improvement in the observation group and 10 cases (23.3%) improved in the observation group. The total effective rate was 95.4%. The results showed that tifluptyline has a good anti-platelet aggregation, the short-term effect of coronary heart disease better.